Ozempic and Wegovy considered ‘available’ after more than 2 years in shortage
The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...
Hims & Hers falls -14.6%
Hims & Hers (HIMS) is down -14.6%, or -$3.25 to $19.00. Published first on TheFly – the ultimate source for real-time, ...
Growing potential for Trump presidency likely helping lift gold to new highs, analyst says
Gold futures hit all-time highs due to election uncertainty and safe-haven demand, and the growing likelihood of a Trump ...
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...
Hims & Hers stock tumbles after Novo's semaglutide taken off shortage list (update)
Shares of Hims & Hers (NYSE:HIMS) fell 15% Wednesday following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no ...
ENDPOINTS NEWS10h
FDA says all ver­sions of Novo's GLP-1 weight loss drugs are now avail­able
The FDA on Wednesday updated its drug shortage database to say that all dosages and versions of Novo Nordisk's Wegovy and Ozempic are ...
Modern Healthcare11h
Telehealth firms courting employers with Ozempic, Wegovy copycats
With the cost of GLP-1s rising for employers, so-called compounded weight-loss drugs have emerged as a more cost-conscious ...